Search results

Altasciences determines the suitability of nano milling for a client’s highly active compound with very poor aqueous solubility and less than desirable bioavailability.

A leading developer of novel cancer therapeutics was experiencing persistent manufacturing process issues. Our engineers were able to diagnose and solve two problems.

Gretchen Green recaps the ARVO 2025 annual meeting, highlighting AI in ophthalmology, gene therapy, and preclinical advances in ocular safety and drug delivery.